5th ALS Drug Development Summit
2026-06-02 - 2026-06-09 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 5th ALS Drug Development Summit returns to Boston as the ultimate platform honing industry R&D for safer, more effect and patient-relevant drugs that serve the community, driving a cure for sporadic and familial ALS.
With a brand-new agenda spanning early target exploration through to clinical design, biomarker strategy, and regulatory engagement, attendees will gain comprehensive insights into genetically validated targets, the evolving biology of TDP 43, adaptive trial design, and embedding the patient voice throughout development.
Join us for 3 days of unmissable data-driven content, with 2 tracks spanning discovery to access for the whole team:
Track A: Discovery, Preclinical & Translational – designed for CSOs, pre-clinical researchers, discovery scientists, directors of biology and research, novel modality scientists, in viva/in vitro modelling experts and many more, connect with an intimate group of discovery and preclinical experts for a more discursive session.
Track B: Clinical & Regulatory – tailor-made for medical directors, CMOs, clinical program leaders, translational and clinical development heads and clinicians and more; share expertise from diverse clinical challenges and innovation in ALS.
Designed for biotech, pharma, academia, and patient advocacy stakeholders, this unique forum will unite 100+ senior experts and 30+ speakers from companies including AbbVie, Biogen, Novartis, Eli Lilly, QurAlis, Prilenia, Sanofi, and many more.
Discover the full 2026 event guide now to explore all speakers and sessions – https://ter.li/28a6lw

5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit
2026-06-02 - 2026-06-04 | Hotel AKA Boston Common, 90 Tremont Street, Boston, MA, 02108, United States
The 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit returns to Boston in June 2026 as the premier industry forum dedicated to advancing extrahepatic LNP delivery and next-generation targeted lipid nanoparticle technologies. As the field moves beyond liver-focused delivery, achieving precise, selective, tissue-specific targeting remains one of the most critical challenges in genetic medicine. With growing industry validation – including strategic acquisitions by AbbVie and Bristol Myers Squibb – confidence in targeted LNP platforms is accelerating across biopharma.
Over 3 content-rich days, 60+ experts from leading biotech, pharma, and academia will share cutting-edge data and practical insights on delivering mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, muscle, and adipose tissue. Attendees will explore novel targeting ligands, active and passive targeting strategies, innovative lipid chemistries, and advanced formulation approaches designed to improve biodistribution, potency, and safety profiles.
The summit will also address critical translational challenges, including targeted LNP analytics, scalability, manufacturability, and immunogenicity – key hurdles in advancing extrahepatic delivery toward clinical success. Through 13+ data-driven case studies, 6 interactive workshops, expert panel discussions, and dedicated networking sessions, participants will gain actionable strategies to accelerate development timelines and de-risk clinical progression.
With representation from pioneering organizations across the delivery ecosystem, this meeting provides a unique opportunity to benchmark progress, forge strategic partnerships, and overcome bottlenecks limiting cell-specific LNP performance. Whether optimizing formulation, engineering targeting ligands, refining preclinical models, or preparing for clinical translation, this summit delivers the technical depth required to stay at the forefront of innovation.
Visit Our Website for More Information.
https://ter.li/rt2poz

10th R&D Procurement & Sourcing in Pharma Summit
2026-06-02 - 2026-06-04 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The Future of R&D Procurement Excellence Starts Here!
The 10th R&D Procurement & Sourcing in Pharma Summit returns to Boston in June 2026 as the definitive meeting place for procurement, sourcing and category management leaders across pre‑clinical and clinical R&D. This flagship event is designed to support procurement teams as they transition from transactional buying to strategic, value‑driven partnership models that accelerate pipeline delivery and protect business continuity.
Bringing together senior R&D procurement leaders from global biopharma, the summit focuses on strengthening sourcing resilience, maximising CRO and CMO partnerships, embedding AI and orchestration tools, and aligning procurement strategy with scientific and operational ambition across the development lifecycle.
Visionary Faculty Includes:

Novartis – Strengthening global sourcing resilience amid geopolitical and supply‑chain disruption
Regeneron Pharmaceuticals – Optimising supplier governance and long‑term strategic partnerships
Vertex Pharmaceuticals – Integrating data, technology and AI to streamline R&D procurement operations
Takeda & UCB – Elevating procurement’s influence through early‑stage R&D decision‑making

Why Attend?

Three days of immersive learning across discovery, pre‑clinical and clinical procurement tracks
30+ expert speakers sharing real‑world case studies and practical, execution‑ready frameworks
Dedicated sessions on AI‑enabled procurement, supplier relationship management and global sourcing resilience
Extensive networking opportunities with peers shaping the future of R&D procurement and sourcing

Join us in Boston to help redefine procurement as a strategic engine for R&D innovation, delivering speed, resilience and measurable supplier value across the development pipeline.

PFS & Injectable Drug Delivery West Coast
2026-06-08 - 2026-06-10 | SAN DIEGO MARRIOTT LA JOLLA, 4240 La Jolla Village Drive, La Jolla, San Diego, CA, 92037, United States
Foster Innovation and Collaboration at the 10th Annual Pre-Filled Syringes and Injectable Drug Devices West Coast Conference!
Join us in June 2026 as SAE Media Group’s renowned West Coast event returns, bringing together biotech pioneers, pharma leaders, and device innovators to shape the future of injectable drug delivery.
This year’s conference will bring a brand NEW focus day followed by the two-day main conference offering an unparalleled platform to explore cutting-edge advances in combination product technology while fostering collaboration between pharma, device developers, and regulators.
Free to Attend for Pharma and Biotech!*
What You’ll Gain:

Actionable insights to strengthen your drug-device portfolio.
Opportunities to network with key players shaping the injectable drug delivery landscape.
A future-focused perspective on innovation, regulation, and patient-centric care.
This must-attend event is your chance to stay ahead in the rapidly evolving injectable drug delivery space. We look forward to welcoming you to the West Coast in June 2026!
Join organizations including: AbbVie, Amgen, Bristol Myers Squibb, Ionis Pharmaceuticals, Protagonist Therapeutics, Genentech and, more

*Terms and Conditions apply
To learn more and register, please click here.

5th World ADC Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The 5th World ADC Summit South Korea (previously World ADC Asia), taking place 9–11 June 2026 in Seoul, stands as the Asia’s premier meeting dedicated to accelerating next‑generation antibody–drug conjugate (ADC) development.
As South Korea rapidly transitions from a biosimilar‑focused market to a global innovator in precision oncology, ADCs have emerged as a centrepiece of this shift. The summit responds to this momentum by offering a comprehensive, end‑to‑end forum covering discovery, preclinical development, clinical translation, and CMC innovation. With more than 300 industry experts expected to attend, the event brings together leading organizations to exchange insights on novel and dual‑payloads, bispecific ADCs, and strategies to overcome Topo‑1 resistance and develop best‑in‑class ADCs.
Whether you are an expert or beginner in the field, join one of our three content tracks spanning early discovery through manufacturing scale‑up to get up to speed with the latest developments.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on targeted protein degradation (TPDs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/qznxdj

World TPD & Induced Proximity Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The World TPD & Induced Proximity Summit South Korea is the first and only Asian industry event dedicated exclusively to advancing targeted protein degradation (TPD) and induced proximity–based therapeutics.
As the global TPD field enters a pivotal era, with the first PROTAC approval on the horizon and multiple candidates progressing through clinical trials, South Korea has emerged as a major innovation hub, fuelled by rapid investment, strategic partnerships, and an expanding biotech ecosystem.
Designed as an end‑to‑end forum for degraders, molecular glues, and degrader antibody conjugates (DACs), the summit brings together international opinion leaders and Korean pioneers to address discovery challenges, translational strategy, clinical development, and emerging platform technologies. Deep‑dive sessions explore novel E3 ligases, AI‑enabled discovery workflows, proteomics‑driven target identification, PK/PD optimization, and case studies showcasing first‑in‑human PROTAC and DAC programs.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/tslwfl

World Bispecific & T-Cell Engager Summit South Korea
2026-06-09 - 2026-06-11 | COEX Magok Lewest, 143 Magokjungang-ro, Gangseo-gu, Seoul, South Korea
The World Bispecific & T‑Cell Engager Summit South Korea is Asia’s first and only industry‑dedicated forum focused on advancing bispecific antibodies and T‑cell engagers (TCEs), modalities that are redefining the therapeutic landscape for solid tumors and immune‑driven diseases. Propelled by landmark regulatory approvals such as tarlatamab and ivonescimab, bispecifics and TCEs have captured global interest for their ability to address previously unmet medical needs.
This inaugural summit brings together international experts and regional leaders for deep‑dive sessions on advanced engineering, co-stimulation strategies, antibody masking, conditional activation, and the design of trispecific and tetraspecific formats. The agenda also explores bispecific ADCs (bsADCs), novel target selection, TCE expansion into autoimmune disease, translational biology, and early clinical readouts shaping development priorities.
As South Korea positions itself as a rising global powerhouse in targeted therapeutics, this summit provides a vital forum for advancing first‑in‑class bispecific and TCE‑based therapies with the potential to transform patient outcomes worldwide.
One Pass, Three Events: Part of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs), Bispecifics, and T-cell engagers, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
To know more visit: https://ter.li/bw174h

8th T-Cell Engager Therapeutics Summit
2026-06-23 - 2026-06-25 | The Westin San Diego Bayview, 400 W Broadway, San Diego, CA, 92101, United States
8th T‑Cell Engager Therapeutics Summit — Your Flagship TCE Meeting
The T‑cell engager field is evolving at an unprecedented pace. With multiple clinical approvals now validating the durability and therapeutic relevance of this modality, and a new wave of next‑generation solid tumor and autoimmune programs rapidly progressing toward the clinic, TCEs have firmly established themselves as one of the most transformative forces shaping the future of immunotherapy.
Over the past year, the landscape has seen a sharp rise in investment, strategic alliances, and high‑value partnerships. Landmark collaborations, including BMS × JanuX Therapeutics, Candid Therapeutics × WuXi Biologics, and AbbVie × EvolveImmune, underscore the growing confidence in immune‑redirecting platforms and the sector’s commitment to accelerating innovation across oncology and autoimmune disease.
Now moving from Boston to San Diego for 2026, the 8th T‑Cell Engager Therapeutics Summit remains the industry’s most comprehensive end‑to‑end meeting dedicated exclusively to advancing, optimizing, and translating TCEs. This case‑study‑driven forum equips engineering, discovery, R&D, translational, and clinical development teams with the actionable insights needed to design safer, more potent, durable, and precisely targeted TCEs for solid tumors. The agenda also shines a spotlight on new applications expanding engager biology into autoimmune and inflammatory indications.
If accelerating your TCE pipeline is a priority, this is the meeting you cannot afford to miss.
What’s New in 2026?
Two Brand‑New Parallel Tracks
Tailor your learning across two dedicated streams: Discovery & Engineering and Preclinical to Clinical Translation, enabling deep dives aligned to your role and pipeline stage.
Fresh Clinical Insights in Combination & Precision Immunotherapy
Hear directly from Amgen and Regeneron as they reveal new clinical evidence on chemo‑immunotherapy integration, co‑stimulation pairings, and combination‑ready TCE design for deeper, more durable responses in solid tumors.
Explore the Full Event Guide
120+ Industry Attendees
28+ Expert Speakers
8+ Hours of Networking
6 Deep‑Dive Workshops
1 Modality at the Center
The Only Forum Advancing TCEs Across Oncology & Autoimmune Disease
View the Full Program – See all sessions, speakers, and workshops: https://ter.li/fulua0

4th Obesity & Weight Loss Drug Development Summit
2026-07-14 - 2026-07-16 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
Welcome to the 4th Obesity & Weight Loss Drug Development Summit – the definitive industry-forum dedicated to redefining the standards of metabolic medicine by mastering precision treatment, preserving functional health, and navigating the high-stakes transition to next-generation oral and multi-agonist therapies.
The obesity therapeutics market has entered a radical transformation. Driven by the unprecedented success of first-generation incretins, the landscape has reached a critical juncture where “simple weight loss” is no longer enough to win. As we move through 2026, the industry is under intense pressure to move beyond BMI-centric endpoints and unlock new levels of quality, targeting the 40% of adults globally who require more than a one-size-fits-all approach. The race is now on to decouple adipose reduction from skeletal muscle atrophy and secure long-term adherence through needle-free, scalable solutions that promise to transform chronic disease management forever.
The 4th Obesity & Weight Loss Drug Development Summit stands as the essential global forum for experts dedicated to accelerating this vital progress. This year, we are diving deep into the game-changing potential of multi-targeted portfolios, novel biological pathways and new modalities for a precision medicine approach, alongside the “Oral-First” revolution.
Hear from the titans of the pharmaceutical industry, including Novo Nordisk, Eli Lilly, and Merck & Co., as well as innovative biotechs such as Veru Inc., Canary Cure, and Metsera, who will share their ground-breaking research on preserving lean mass and preventing post-treatment weight regain.
Don’t miss this pivotal opportunity to network with 120+ leading experts in the field of advanced obesity therapeutics. Forge crucial collaborations and be part of the solution that will define the 2026 pipeline.
View the full event guide: https://ter.li/p453jn

2nd Operationalize: Expanded Access Programs Summit West
2026-07-14 - 2026-07-16 | Hyatt Centric Fisherman’s Wharf, 555 North Point Street, San Francsico, CA, 94133, United States
Across the West Coast, Expanded Access Programs are entering a new phase. More companies are launching EAPs earlier in development, supporting patients for longer durations, and extending access beyond the U.S. into increasingly complex global markets. What was once a reactive, exception-based activity is now a visible, repeatable function – bringing heightened expectations around governance, post-trial access, sustainability, and real-world insight generation, all while ensuring patients are not delayed or disadvantaged.
The 2nd Operationalize: Expanded Access Programs Summit West arrives at a critical moment. Purpose-built for West Coast biotech and pharma teams, this summit brings together senior leaders across Access, Medical Affairs, Clinical Operations, Regulatory, and Clinical Supply to share how EAPs are being designed, governed, and scaled in today’s environment.
Over three focused days, the summit tackles the most pressing questions facing EAP teams in 2026 – from navigating evolving U.S. and global regulatory expectations, to enabling providers and patient advocates, designing post-trial access strategies, managing long-duration and rare disease programs, and applying real-world insights without slowing access.
This is not a theoretical discussion. It is a peer-led, non-competitive forum for teams responsible for delivering access at scale – and for those shaping what Expanded Access must become next.
To know more visit: https://ter.li/gk0u1gt1

6th mRNA-Based Therapeutics Summit
2026-07-20 - 2026-07-22 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
The 6th mRNA‑Based Therapeutics Summit: Accelerating the Next Era of mRNA Medicines
The global mRNA landscape is advancing at unprecedented speed, propelled by scientific breakthroughs and high‑impact biopharma investment. Recent acquisitions – including Eli Lilly and Orna, BMS and Orbital, AbbVie and Capstan, and BioNTech and CureVac – underscore the momentum behind emerging modalities such as in vivo CAR‑T, gene editing, and cancer immunotherapies as they move closer to clinical validation and commercial potential.
Amid this rapid evolution, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world’s most influential meeting dedicated to mRNA science and drug development. Bringing together 350+ global leaders from established pharma innovators to trailblazing start‑ups – including Moderna, Pfizer, AstraZeneca, Sanofi, ParcelBio, CaVos Therapeutics and Kernal Biologics – as well as regulators from the US FDA, MHRA and EMA, the summit serves as the central forum shaping the future of mRNA technology.
This year’s revitalized agenda spans three core tracks – Discovery, Pre‑Clinical & Clinical Development, and Manufacturing & CMC – while introducing two brand‑new focus days on AI‑Driven mRNA Design and Next‑Generation Delivery Technologies. Across scientific sessions, case studies, and collaborative discussions, attendees will gain exclusive access to emerging data, regulatory expectations, and the partnerships driving mRNA toward its next frontier.
With 1,988 mRNA assets currently moving through global pipelines, the field is scaling faster than ever. The 2026 summit is strategically timed to spotlight major advancements across linear, circular, and self‑amplifying RNA platforms; next‑generation vaccine innovation and expanding clinical progress in oncology, rare diseases, autoimmune conditions, and beyond.
As the flagship global gathering for mRNA innovators, this summit remains the definitive place to connect with key decision makers, forge new strategic partnerships, and refine development and delivery strategies. From protein replacement to cell and gene therapeutics and transformative delivery technologies, the 6th mRNA‑Based Therapeutics Summit equips teams with the insights, networks, and momentum needed to accelerate candidates to clinical and commercial success and ultimately deliver life‑changing medicines to patients worldwide.
To know more visit: https://ter.li/axdw1v

5th Liquid Biopsy for Precision Oncology Summit East Coast
2026-07-20 - 2026-07-22 | Westin Boston Seaport, 425 Summer Street, Boston, MA, 02210, United States
The 5th Liquid Biopsy for Precision Oncology Summit East Coast returns as your laser-focused forum dedicated to the acceleration, progression and real-world adoption of liquid biopsies. Expect to unite with 100+ biopharma professionals from Pfizer, AbbVie, Takeda, AstraZeneca, GSK and more to redefine your clinical trial strategies and advance oncology drug development forward.
Boasting a speaker faculty consisting of over 70% large pharma, alongside leading biotech and consortia, this year’s meeting will not just be a forum to listen. It will be where the practical conversations shaping future decisions on patient stratification, MRD implementation and dose optimization happen in real time.
Take a sneak peek at what lies ahead this year:

Identify why pharma must be the ones to lead early detection in a session led by the Global Senior Director, Early Detection at AstraZeneca
Utilize ctDNA dynamics as an early measure of treatment effect to go beyond RECIST in a presentation hosted by the Chief Executive Officer at Marengo Therapeutics
Hear how senior pharma leaders at AbbVie, Takeda, AstraZeneca and GSK are rewriting drug development decisions with novel liquid biopsies
Discover how you can accelerate clinical development with ctDNA clearance and multi-omic profiling in an exclusive discussion moderated by the Director, Next-Generation Diagnostics at Novartis

Whether you’re evaluating the right liquid biopsy platform for your specific trial, looking to gain peer-insight into ctDNA and multi-omic profiling, or aligning internal strategies with evolving regulatory expectations, this meeting will provide you with the clarity, and confidence to take that next step.
Together let’s harness the power of liquid biopsies to drive smarter, better and more precise clinical decisions for patients in need.
To learn more and register, please click here.

6th Medical Device Software Development Summit
2026-07-21 - 2026-07-23 | Hotel AKA Back Bay, 154 Berkeley St, Boston, MA, 02116, United States
The 6th Medical Device Software Development Summit returns this July in Boston and brings together the specialists who are defining how AI-driven and software-based medical devices are built, validated, and submitted in an increasingly complex regulatory environment.
AI is accelerating innovation faster than traditional compliance models can keep up. FDA expectations for AI-enabled devices continue to evolve, cybersecurity scrutiny is intensifying, and global regulations such as the EU AI Act are adding new layers of complexity. The summit provides the clarity needed to navigate this shift by focusing on the real-world application of AI, automation, model development, and lifecycle management in regulated device environments.
Across three days of technical sessions and workshops, you will learn how leading teams are integrating AI responsibly, reducing regulatory risk, and strengthening product development pipelines. Speakers will break down practical frameworks for safe and compliant AI integration, including model validation, data quality, transparency expectations, documentation strategies, and global submission planning. Sessions also explore how continuous deployment and code generation tools can be aligned with compliance requirements.
You will:

Gain clear insight into evolving FDA expectations for AI-enabled and learning devices
Learn best practices for AI model development, validation, and deployment across the product lifecycle
Explore cybersecurity architectures that protect AI-driven systems from emerging risks
Understand how companies are modernizing development workflows through automation and AI-assisted engineering while maintaining compliance
Benchmark with software, regulatory, quality, cybersecurity, and product leaders who openly share real-world implementations and lessons

With a focused senior-level audience, discussions are practical, detailed, and grounded in real use cases instead of high-level theory. If your team is building or validating AI-enabled medical device software in 2026, this summit is the most concentrated source of guidance on how to innovate safely, accelerate approvals, and future-proof your roadmap in a rapidly shifting landscape.
Join the community leading the next generation of AI-driven medical device software and gain the insight and tools needed to advance your program with confidence.
To learn more and register online, please click here.

9th International Neoantigen Summit
2026-07-21 - 2026-07-23 | Park Plaza Amsterdam Victoria, Damrak 1-5, 1012 LG, Amsterdam, Netherlands
As the only conference focused on neoantigens, the 9th International Neoantigen Summit returns to Amsterdam as the most timely and essential gathering for the field. As your only chance this year to learn about the latest clinical data in the field and address the full translational journey – from antigen identification and validation through to biomarker strategy, clinical trial readouts and therapeutic efficacy – it’s not one to miss.
With a sharp focus on optimising translational testing, strengthening neoantigen validation and advancing novel personalised and off‑the‑shelf approaches, the conference is designed to help the industry streamline clinical trials and develop durable therapies with high immune response.
Over 3 immersive days, the summit will unite 70+ C‑level executives, directors, heads and senior scientists from leading biopharma organisations across Europe and the US. Attendees span:

Cancer immunotherapy
Antigen discovery
Bioinformatics
AI‑driven validation
Preclinical and clinical development
Regulatory strategy

All brought together by a shared mission to unlock the full potential of neoantigen‑targeted therapies.
With 6 new speaking companies, including Black Canyon Bio, CellVax Therapeutics, Echo Immune, Epitopea, Khosen Bio and Treos Bio, the summit convenes industry pioneers including Nykode Therapeutics, Evaxion, Geneos, and other leading innovators shaping the next generation of immunotherapies. Every session is curated for relevance, and every interaction is designed to foster meaningful collaboration.
Participants can expect critical clinical data updates, practical insights into bioinformatics and AI applications, strategies for clinical trial design and execution, and guidance on translating preclinical findings into successful clinical outcomes. More than a conference, this is the only annual checkpoint for the neoantigen community – a one‑stop platform to benchmark progress, uncover breakthroughs and build the partnerships that will drive the next wave of neoantigen‑targeted therapies forward.

4th ADC Linker & Conjugation Summit
2026-07-28 - 2026-07-30 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
4th ADC Linker & Conjugation Summit
Linking Chemistry to Clinical Success Through Better ADC Design

When? July 28-30, 2026
Where? Boston, MA

ADC development is evolving fast, with developers pushing beyond traditional cytotoxins into dual‑payload constructs, high‑DAR species, degrader–antibody conjugates, and next‑generation modalities. This surge in innovation is placing new pressure on linker architecture and conjugation chemistry to improve stability, reduce off‑target toxicity, and maintain manufacturability at scale.
The 4th ADC Linker & Conjugation Summit returns this July as the only meeting dedicated exclusively to overcoming these chemistry‑centric challenges. Built specifically for ADC chemists, protein engineers, and bioconjugation specialists, the summit offers a highly curated setting where every session speaks directly to the scientific bottlenecks shaping next‑generation ADC performance. Attendees join peers with the same technical focus, ensuring every conversation is relevant and grounded in real‑world ADC development needs.Across three focused days, more than 80 scientific experts will dissect the mechanisms driving linker stability, conjugation precision, and payload behavior. The program features 20+ industry‑led case studies covering homogeneous ADC design, controlling premature payload release, dual‑payload engineering, hydrophobicity‑driven aggregation, and the integration of predictive modeling into conjugation strategies. These sessions reflect broader industry priorities, where site‑specific conjugation, next‑generation linkers, and stability optimization remain top areas of innovation.
This year introduces expanded workshops and interactive debates, including new sessions examining how to more effectively connect linker chemistry to translational outcomes and how to redesign payloads using emerging linker technologies. The 2026 meeting also welcomes 17 new speakers from 13 new companies, offering fresh insight into the rapidly diversifying toolkit available for ADC design.
For scientists working at the core of ADC chemistry, this summit provides a rare opportunity to benchmark strategies, challenge assumptions, and contribute to the next decade of linker and conjugation innovation.
View the full program and explore the 2026 agenda
Download the event guide here: https://ter.li/7pj7r6

5th In Vivo Cell Engineering & Gene Editing Summit
2026-07-28 - 2026-07-30 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
The 5th In Vivo Cell Engineering & Gene Editing Summit returns as the leading industry meeting dedicated to advancing the next generation of in vivo delivery platforms, gene editing tools, and translational strategies that support safe, precise, and scalable genetic medicines. Designed for scientists, technical leaders, and strategic decision-makers across biopharma, this summit provides a focused forum to exchange practical insights that directly influence scientific and clinical progress.
This year’s faculty brings together experts from cutting-edge biotechnology companies and global pharmaceutical organizations, including leaders from AstraZeneca, Pfizer, Eli Lilly, Ensoma, Capstan Therapeutics, Verve Therapeutics, nChrioma Bio, and more. Their collective experience spans delivery system innovation, payload engineering, translational development, and early clinical execution, giving delegates a clear view of what is required to successfully advance in vivo platforms.
Over three days of data-driven discussion, attendees will explore the latest advancements in lipid nanoparticle engineering, viral and nonviral vector optimization, capsid evolution, and emerging delivery technologies for targeted, efficient editing. Sessions will detail how teams are engineering payloads to enhance potency, durability, safety, and manufacturability. Speakers will also share frameworks for designing rigorous preclinical packages that address biodistribution, immunogenicity, and off-target risk early in development.
The summit places a strong focus on translational and early clinical learnings, with case studies that reveal how organizations are approaching dose selection, biomarker development, patient monitoring, and regulatory positioning. These insights provide an unfiltered look at what has worked in real programs and how teams are adjusting strategies to improve clinical readiness.
Delegates will benefit from a mix of scientific depth and strategic clarity. Whether you are building new delivery platforms, advancing editing tools, refining analytical approaches, or preparing a therapy for first-in-human studies, this meeting helps you benchmark your progress and sharpen decision-making.
Join peers who are driving the future of in vivo gene editing and cell engineering. This summit delivers the connections, evidence-based insights, and collaborative environment needed to progress transformative genetic medicines.
To learn more and register online, please click here.

3rd Lab Ops & Facility Management for Biopharma West Summit
2026-08-11 - 2026-08-13 | The Westgate Hotel, 1055 2nd Ave, San Diego, CA, 92101, United States
The 3rd Annual Lab Ops & Facility Management for Biopharma West Summit is the West Coast’s dedicated meeting for Lab Operations and Facilities leaders who are being asked to do more with less while keeping scientists productive and R&D environments running at the highest standard. With tighter budgets, workforce fluctuations, and rapid pipeline shifts reshaping day-to-day priorities, this summit is built to help teams maintain operational excellence without compromising safety, compliance, or lab uptime.
Taking place August 11–13, 2026 in San Diego, the program brings together 70+ senior leaders across lab operations, facilities, scientific services, and operational support from fast-growing biotechs, established pharma, and leading CDMOs/CROs. Expect operator-led discussions centered on the decisions Lab Ops teams are making right now: how to prioritize when everything feels urgent, how to streamline workflows to protect throughput, and how to build resilient support models that hold up through organizational change.
The agenda tackles the themes shaping lab performance in 2026. You’ll explore how teams are building resilient operations in volatile environments, integrating automation and applied AI to reduce manual burden and improve decision-making, and strengthening vendor partnerships and procurement strategy to spend with intention while reducing downtime risk. You’ll also hear how organizations are planning flexible lab and facility footprints that can adapt as research needs evolve, including approaches to facility transitions and future-proofing infrastructure.
A key feature is the pre-conference workshop day, featuring two hands-on sessions designed for immediate application. Workshop A provides a practical toolkit for implementing AI in lab operations, with proven use cases and guidance for integrating tools into existing systems without disrupting daily work. Workshop B dives into vendor strategy to reduce spend and maximize operational leverage, with actionable approaches to consolidation, identifying cost-saving opportunities, and maintaining service excellence.
With 20+ expert speakers, two interactive workshops, and 6+ hours of dedicated networking, this summit is built for honest benchmarking, meaningful connections, and takeaways you can implement immediately to maintain excellence and better support scientists.
To know more visit: https://ter.li/jgbff6e1

5th Oligonucleotides Analytical Development & CMC Summit
2026-08-17 - 2026-08-19 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
Taking place in Boston (August 17–19, 2026), the 5th Oligonucleotide Analytical Development & CMC Summit is a premier event dedicated to advancing analytical and CMC strategies for oligonucleotide therapeutics. Bringing together experts from Alnylam, Biogen, Ionis Pharmaceuticals, Amgen, and Avidity Biosciences, the meeting tackles key challenges in impurity control, complex chemistries, and scalable manufacturing. Attendees will gain insights into cutting-edge analytical tools including mass spectrometry and sequencing, alongside evolving global regulatory expectations. Covering modalities such as ASOs, siRNA, and conjugates, the summit provides practical frameworks to improve product quality, comparability, and regulatory readiness. Connect with 90+ industry leaders and accelerate development from early-stage research through to commercialization. Visit the website for more information.
To learn more and register online, please visit: https://ter.li/l10canku

6th Oligonucleotides for CNS Summit
2026-08-19 - 2026-08-21 | The Colonnade Hotel, 120 Huntington Ave, Boston, MA, 02116, United States
The 6th Annual Oligonucleotides for CNS Summit USA returns to Boston on 19–21 August 2026, uniting 160+ leaders across pharma and biotech to accelerate the discovery, translation and clinical success of CNS‑targeted oligonucleotide therapies. As advances in RNA chemistry, delivery technologies and clinical evidence unlock previously undruggable CNS targets, this meeting is the industry’s most focused forum to benchmark what is truly working — and what’s next.
Across three highly interactive days, hear the latest data and strategy from companies including Eli Lilly, Stoke Therapeutics, Dyne Therapeutics, Creyon Bio and Quiver Bioscience, covering ASOs, siRNAs, saRNAs and aptamers. Dive into real‑world challenges around CNS penetration, BBB shuttles, intrathecal vs systemic delivery, splice modulation, chemistry and conjugation design, PK/PD translation, safety and regulatory alignment — all through case studies, panels, workshops and roundtables designed for open, precompetitive discussion.
With expanding pipelines, growing competition and rising expectations for clinical impact beyond rare disease, this summit offers a uniquely concentrated environment to learn from clinical‑stage programs, stress‑test your development strategy and connect with the scientists and decision‑makers shaping the future of CNS oligonucleotides.
Find out more today – https://ter.li/twgv2av6

6th iPSC Drug Development Summit
2026-09-09 - 2026-09-10 | Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, MA, 02128, United States
As iPSC therapies transition from promise to clinical reality, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists, CMC experts, and decision-makers, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization.
This year’s agenda is designed to address the most pressing challenges across the iPSC pipeline, with a sharp focus on scalability, manufacturability, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks, covering preclinical development and process development & CMC, including genome editing strategies, donor and cell line selection, functional quality control, and GMP-ready manufacturing approaches.
The summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease, diabetes, oncology, and ocular disorders.
Speaker highlights include:

Yanzheng Liu, Senior Director, Aspen Neuroscience
Rachel Knopp and Yongting Wang, Astellas Pharma
William Hendriks, Director of PSC Biology, BlueRock Therapeutics
Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics
Alex Ng, Chief Scientific Officer, GC Therapeutics
Marcella Garita-Hernandez, Head of iPS Core, Harvard Medical School

With contributions from organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks.
Designed for professionals actively building iPSC pipelines, the summit offers an end-to-end view of the field, alongside collaborative networking with peers across biopharma, academia, and investment. From optimizing early discovery decisions to ensuring commercial readiness, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies.
Find out more here: https://ter.li/japojzin
This meeting is free to attend* for biopharma and academics.

9th Neuropsychiatric Drug Development Summit
2026-09-15 - 2026-09-17 | Revere Hotel Boston Common, 200 Stuart Street, Boston, 02116, United States
The Neuropsychiatric Drug Development Summit is the definitive meeting for biopharma leaders shaping the future of psychiatric R&D. At a time of renewed momentum in neuropsychiatry, this summit brings together senior decision‑makers to redefine how the industry translates science into successful, patient‑centred therapies.
Across discovery, translational science, and clinical development, the agenda showcases the most promising advances in the field — from psychedelics, muscarinics, orexins, and novel neuroplasticity approaches to cutting‑edge translational tools such as EEG, digital and speech biomarkers, sleep endpoints, and smarter patient stratification. Attendees will gain practical insights into overcoming placebo response, heterogeneity, and late‑stage failure through biology‑driven, regulatory‑ready strategies.
Designed for meaningful connection and collaboration, the summit offers an intimate, highly interactive environment to exchange data, challenge assumptions, and build partnerships with peers tackling depression, schizophrenia, bipolar disorder, anxiety, PTSD, and addiction. Join the global community accelerating the next era of precision psychiatry.
Find out more today – https://ter.li/rt2cakk3

COPD Drug Development Summit
2026-09-15 - 2026-09-17 | Homewood Suites by Hilton Boston Seaport District, 670 Summer Street, Boston, MA, 02210, United States
The First Industry‑Led Meeting Dedicated to Advancing Next‑Generation COPD Therapeutics
The COPD Drug Development Summit is the first and only industry‑driven forum designed to accelerate meaningful innovation in chronic obstructive pulmonary disease.
With the approval of the first biologic therapy marking a historic turning point, COPD R&D is entering a new era, one defined by deeper biological understanding, more precise patient segmentation, and a renewed push toward disease‑modifying treatments.
This summit convenes leading scientists, clinicians, regulatory experts, and biotech innovators to address the scientific and operational barriers that have long constrained progress.
Over three days, attendees will explore the most urgent and promising areas shaping the future of COPD therapeutics.
Core themes include novel target discovery, translational alignment, and smarter clinical trial design that reflects the heterogeneity of COPD endotypes.
The program also examines the limitations of traditional endpoints such as exacerbations and FEV₁, highlighting next‑generation measures, including imaging‑based progression tools, AI‑enabled assessment, and biomarkers capable of capturing early disease activity and therapeutic impact.
With 65+ industry leaders and 16+ expert speakers from organisations including Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Generate Biomedicines, and Ethris, the summit offers a uniquely concentrated environment for scientific exchange and partnership building.
Participants will engage in 7+ hours of structured networking, panel discussions, and case‑study‑driven sessions that illuminate both the opportunities and the remaining challenges in COPD drug development.
Designed for discovery scientists, translational researchers, clinical developers, regulatory strategists, and biotech executives, this event provides a rare chance to shape the next chapter of COPD innovation.
As the field moves toward more personalised, mechanism‑driven approaches, the COPD Drug Development Summit serves as a critical platform for aligning science, strategy, and regulatory confidence to deliver better outcomes for millions of patients worldwide.
Register now: https://ter.li/kvevwxqk

11th CAR-TCR Summit
2026-09-15 - 2026-09-17 | The Westin Boston Seaport District, 425 Summer Street, Boston, MA, 02210, United States
All eyes are on the next wave of CAR and TCR innovation. Success is no longer defined by clinical wins alone, but by smarter biological design, delivery strategies and manufacturing breakthroughs to lower COGs, expand patient access and secure commercial viability.
With this, the 11th CAR-TCR Summit is making its hotly anticipated return to Boston, September 15-17.
View the agenda here.
Crafted in collaboration with industry veterans and spanning four tracks across the entire development life cycle, the program offers a clear, strategic view of the next era of cell therapy. Expect first hand insight into cutting-edge in vivo and next generation CAR and TCR innovations, hear unpublished clinical data across emerging indications, and learn from real world automated manufacturing case studies shaping commercial readiness.
Beyond the science, you’ll gain direct access to investors to align on where capital and strategic partnerships are moving next, complemented by high-value networking with C-suite executives and academic KOLs to safegaurd every stage of your cell therapy development pipeline.
If you’re committed to driving the innovation and commercial readiness needed to make CAR-T therapies safer, more effective, scalable, and accessible to the patients who need them most, then this is the meeting for you.
Download your copy of the agenda.

Measuring Patient Engagement Summit Europe
2026-09-15 - 2026-09-17 | Hilton London Kensington, 179-199 Holland Park Ave, London, W11 4UL, United Kingdom
The Measuring Patient Engagement Summit Europe is the leading industry forum dedicated to supporting biopharma in quantifying and demonstrating the true impact of patient engagement. As regulatory expectations rise and internal stakeholders demand a clearer return on investment, the need for robust, evidence-based frameworks has never been greater. This three-day summit brings together over 70 senior leaders across patient engagement, advocacy, insights, experience, and medical affairs to address one of the industry’s most pressing challenges – moving from activity-based reporting to measurable impact and defensible KPIs.
Designed to bridge the gap between strategy and proof, the event focuses on establishing credible, comparable, and actionable metrics that demonstrate how patient engagement influences decision-making across the product lifecycle. Attendees will gain practical insights into how patient input drives improvements in protocol design, accelerates clinical trial recruitment, supports regulatory alignment, and strengthens market access outcomes.
Through a combination of real-world case studies, expert-led discussions, and collaborative sessions, the summit offers a unique opportunity to benchmark approaches, co-develop frameworks, and create a shared language of value recognised by regulators, payers, and patients alike. By equipping participants with proven methodologies and peer-tested tools, the event empowers organisations to embed patient engagement as a strategic, data-driven driver of innovation – ensuring its impact is both defensible and impossible to ignore.
Agenda Highlights Include:

Moving beyond activity-based KPIs to define and measure meaningful patient engagement impact
Demonstrating measurable outcomes across clinical trial design, recruitment, and retention
Quantifying the influence of patient insights on regulatory, payer, and market access decisions
Developing credible and standardised frameworks to benchmark engagement success
Translating patient experience data into tangible clinical and commercial value
Aligning patient engagement strategies with ESG and broader organisational priorities
Building a common language of value recognised across industry stakeholders

This summit provides a critical platform for advancing the measurement of patient engagement, enabling organisations to shift from intention to evidence and truly demonstrate the value of patient-centric approaches.
Get your copy of the agenda now to learn more: https://ter.li/fy580o27.

4th TRP Supply Chain & Manufacturing Summit
2026-09-15 - 2026-09-17 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
4th TRP Supply Chain & Manufacturing Summit (September 15–17, 2026 | Boston, MA)
Radiopharmaceuticals are entering a defining stage of development. As clinical programs advance into Phase II, Phase III, and commercial readiness, the ability to manufacture and deliver therapies reliably has become one of the industry’s greatest challenges. Rising demand for isotopes, infrastructure constraints, workforce shortages, evolving regulatory expectations, and the unique realities of short half-life materials are placing unprecedented pressure on supply chain and manufacturing teams.
The 4th TRP Supply Chain & Manufacturing Summit is the only industry-focused forum dedicated exclusively to the supply chain, manufacturing, CMC, quality, and logistics challenges impacting radiopharmaceutical development. Bringing together 60+ senior leaders from pharma, biotech, CDMOs, isotope providers, and logistics organizations, the meeting is designed to help attendees overcome the operational bottlenecks that stand between scientific breakthroughs and patient delivery.
Across two conference days and interactive workshops, attendees will gain practical insights to:

Strengthen isotope supply resilience across established and emerging alpha and beta emitters
Scale manufacturing operations to support late-stage clinical trials and commercialization
Evaluate build vs. buy manufacturing strategies and optimize CDMO partnerships
Implement automation and digital solutions to improve consistency, throughput, and compliance
Optimize logistics and distribution networks for time-sensitive radiopharmaceutical therapies
Navigate evolving regulatory expectations with greater confidence and preparedness

Featuring experts from AstraZeneca, Bayer, Telix Pharmaceuticals, Cellectar Biosciences, Ratio Therapeutics, Convergent Therapeutics, Molecular Partners AG, Purdue University, and the University of Alabama at Birmingham, the summit delivers real-world case studies and practical strategies from organizations actively addressing today’s most pressing supply chain and manufacturing challenges.
With 10+ hours of dedicated networking, attendees can benchmark approaches, exchange lessons learned, and build the partnerships needed to move radiopharmaceutical therapies from bench to patient reliably and at scale.

5th Lipid Nanoparticles Development Summit Europe
2026-09-23 - 2026-09-24 | Dorint Kurfürstendamm Berlin, Augsburger Strasse 41, Berlin, 10789, Germany
The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23rd – 24th September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle systems across mRNA, DNA and gene editing therapies. With interactive discussions and real-world case studies, this event delivers actionable insights to accelerate safe, targeted and clinically viable delivery platforms.
To learn more and register online, please visit: https://ter.li/mft1fbw0

7th Genome Editing Therapeutics Summit
2026-09-28 - 2026-09-30 | Hilton Boston Logan Airport, One Hotel Dr, Boston, MA, 02128, United States
The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options.

But intent and support alone won’t get these therapies to patients. Developmental, manufacturing, and regulatory challenges still stand between the lab and the patients waiting.
That’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting.
Join R&D, preclinical, translational, regulatory, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most?
Don’t miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.
What’s New in 2026?
In 2026, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy, the decisions made now will determine which assets reach patients.
At this year’s summit you will:

Delve into extrahepatic delivery strategies to widen your technology across multiple disease indications

Learn from clinical companies building robust IND packages to fast-track development

Evaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile

Explore the Brand-New Agenda to Discover:

3 days of content to find the sessions your program needs most

50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage

80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers

64% in vivo & 36% ex vivo agenda to fit your route of delivery

2 brand-new workshops

View the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy

10th IPF Summit
2026-09-29 - 2026-10-01 | Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA, 02215, United States
10th Anniversary Edition of the IPF Summit –
September 29 – October 1, 2026 | Boston, MA
For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher.
Following a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb, United Therapeutics, and Boehringer Ingelheim, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge, the question is no longer can we develop treatments, but how to do so smarter, faster, and with meaningful differentiation.
The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this challenge head-on.
Bringing together 150+ experts across discovery, translational science, and clinical development, from organizations including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, and many more, the summit offers a uniquely integrated view of the scientific, clinical, and strategic decisions shaping the next decade of IPF innovation.
Across dedicated content tracks, dive into emerging biology and novel targets to unlock new therapeutic avenues, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape
New for 2026 includes a dedicated ILD & PPF Focus Day, designed to unpack the complexity of fibrotic lung diseases beyond IPF, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.
With 8+ hours of networking in an intentionally intimate setting, the summit is built for honest, high-value discussions, giving you direct access to the people shaping the future of pulmonary fibrosis drug development.
Whether you’re advancing early discovery, translating assets into the clinic, or positioning therapies in a crowded market, this is where the field aligns on what success now looks like, and how to achieve it.
Find out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk

Designing the AI-Enabled Life Sciences Workforce Summit Europe
2026-09-29 - 2026-09-30 | Essential by Dorint Basel City, Schönaustrasse 10, Switzerland, Basel, 4058, Switzerland
AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution.
The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built specifically for senior HR leaders to tackle this challenge head-on. Bringing together CHROs and workforce transformation leaders from leading drug developers, this is where strategy meets execution – and where organisations learn how to redesign work, skills, and operating models to deliver measurable business impact at scale.
At a time when life science organisations must drive productivity, innovation, and growth without increasing headcount, this event provides the practical frameworks, peer insights, and proven strategies you need to move faster with confidence.
This is not a conference about AI trends – it is a working forum focused on how life sciences organisations are redesigning work, workforce strategy, and operating models in response to AI.
Across two highly interactive days, you will learn directly from leaders who are actively transforming their organisations – moving beyond pilots to deliver enterprise-wide impact. Through a unique blend of case studies, discussion, and working sessions, you will leave not only inspired but equipped with clear, actionable next steps.
For more information and to register online, please click here.

5th mRNA Process Development & CMC Summit 2026
2026-09-29 - 2026-10-01 | Wyndham Boston Beacon Hill, 5 Blossom St, Boston, MA, 02114, United States
The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy.
As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA therapeutics, including senior decision-makers from GSK, Eli Lilly, Centivax, Circurna, Sanofi, BioNTech and more!
From scaling processes and strengthening analytical capabilities to navigating global expansion and clinical readiness, this is where the industry’s most pressing CMC challenges are tackled head-on.
Find out more: https://ter.li/peoi4f1e
